Pathstone Holdings
ONC

Pathstone Holdings’s BeOne Medicines Ltd ONC Stock Holding History

Pathstone Holdings’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$266K Sell
932
-73
-7% -$21.5K ﹤0.01% 2117
2026
Q1 		$298K Sell
1,005
-113
-10% -$36.6K ﹤0.01% 1977
2025
Q4 		$340K Buy
1,118
+145
+15% +$47.5K ﹤0.01% 1909
2025
Q3 		$332K Buy
+973
New +$295K ﹤0.01% 1985
2024
Q4 		– Sell
-920
Closed -$207K – 2415
2024
Q3 		$207K Buy
+920
New +$166K ﹤0.01% 2158

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pathstone Holdings's ONC Position: Q2 2026 in Review

Pathstone Holdings reduced its BeOne Medicines Ltd (ONC) stake by 7.3% in Q2 2026, selling an estimated $21.5K and leaving 932 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #2117.

Pathstone Holdings first reported a position in ONC in Q3 2024 and has held it in 5 quarters since. The position peaked at $340K in Q4 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Pathstone Holdings held 932 shares of BeOne Medicines Ltd worth $266K as of Q2 2026.
  • Pathstone Holdings sold 73 BeOne Medicines Ltd shares in Q2 2026, an estimated $21.5K.
  • BeOne Medicines Ltd made up ﹤0.01% of Pathstone Holdings's portfolio in Q2 2026, its #2117 holding.
  • Pathstone Holdings first reported a position in BeOne Medicines Ltd in Q3 2024 and has held it in 5 quarters since.
  • Pathstone Holdings's BeOne Medicines Ltd position peaked at $340K in Q4 2025.
  • 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.